Connect your AI

Allogene Therapeutics ALLO Total Equity

Total Equity at other companies

Bristol-Myers SquibbBMY

$20.07B+15.4%

Gilead SciencesGILD

$23.52B+22.7%

PrecigenPGEN

$20.24M+244%

CRISPR TherapeuticsCRSP

$1.81B-0.8%

Sana BiotechnologySANA

$119.24M-43.0%

CytomX TherapeuticsCTMX

$319.94M+1,177%

Other financials

Income statement

Revenue-—

Operating income-$46.1M+29.3%

Net income-$42.6M+28.7%

EPS (diluted)-$0.18+35.7%

Balance sheet

Cash & equivalents$40.6M-23.0%

Total debt$81.1M-8.9%

Total assets$396.0M-22.1%

Cash flow

Operating cash flow-$12.9M+75.6%

CapEx$9.0K-90.9%

Free cash flow-$12.9M+75.6%

Valuation

Market cap$711.02M+164%

Enterprise value$751.47M+146%

Profitability

Operating margin-1,241,813.6%-2,018,140pp

Net margin-1,170,863.6%-2,007,890pp

FCF margin-913,609.1%-1,474,890pp

Returns & leverage

Return on equity-52.3%-5.7pp

Debt / equity0.3×+0.1×

Current ratio9.6×-0.1×

Where this comes from

Reported directly by Allogene Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Allogene Therapeutics's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Allogene Therapeutics's total equity?: Allogene Therapeutics (ALLO) reported total equity of $278.88M in Q1 2026.
How has Allogene Therapeutics's total equity changed year-over-year?: Allogene Therapeutics's total equity decreased by 27.6% year-over-year, from $385.39M to $278.88M.
What is the long-term trend for Allogene Therapeutics's total equity?: Over 5 years (2020 to 2025), Allogene Therapeutics's total equity has grown at a -22.0% compound annual growth rate (CAGR), from $1.01B to $292.54M.
What does total equity mean?: Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.